{"gene":"APOA5","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2021,"finding":"ApoA5 lowers triglycerides by associating with and suppressing the ANGPTL3/8 complex, thereby relieving ANGPTL3/8-mediated LPL inhibition; ApoA5 has no direct effect on LPL itself, nor does it suppress LPL inhibition by ANGPTL3, ANGPTL4, or ANGPTL4/8 alone.","method":"Immunoprecipitation-MS, Western blotting, biolayer interferometry, functional LPL enzymatic assays, kinetic analyses of LPL activity","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical methods (IP-MS, biolayer interferometry, functional LPL assays) in a single rigorous study with clear mechanistic conclusion","pmids":["33762177"],"is_preprint":false},{"year":2005,"finding":"The APOA5*3 haplotype-defining S19W (c.56C>G) variant reduces ApoAV secretion by ~50% from hepatic cells; molecular modeling shows Trp-19 increases the angle of insertion of the signal peptide at the lipid/water interface, predicting impaired translocation, confirmed by reduced secretion of a Trp-19-SEAP fusion protein vs. Ser-19-SEAP.","method":"Molecular modeling of signal peptide, in vitro secretion assay (HepG2 cells transfected with SEAP fusion constructs), in vitro transcription/translation assays, primer extension inhibition assays, luciferase reporter assays (Huh7 cells)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution/functional cell assay with mutagenesis, supported by molecular modeling and multiple orthogonal methods in a single study","pmids":["15941721"],"is_preprint":false},{"year":2007,"finding":"ApoA5 delivered to livers of APOC3 transgenic mice reduces plasma TG via enhanced VLDL catabolism (not altered production), reduces apoC-III content in VLDL, and modulates HDL maturation by increasing apoA-I and apoE content and LCAT activity in HDL.","method":"Adenovirus-mediated hepatic gene transfer of apoA-V cDNA in APOC3 transgenic mice; plasma lipoprotein fractionation, LCAT activity assay, cholesterol efflux assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo gain-of-function with multiple biochemical readouts, mechanistic pathway placement","pmids":["17438339"],"is_preprint":false},{"year":2008,"finding":"Several rare APOA5 missense variants (E255G, G271C, H321L, G185C) reduce in vitro LPL activation when using VLDL as substrate; truncation variants (Q139X, Q148X, G271C) abolish binding to LDL-family receptors LR8 and LRP1, indicating that C-terminal lipid-binding domains are required for receptor interaction.","method":"Sequencing of APOA5 in hypertriglyceridemic patients; in vitro LPL activity assay with VLDL substrate; receptor binding assays with LR8 and LRP1","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic and binding assays with multiple mutant constructs","pmids":["18635818"],"is_preprint":false},{"year":2013,"finding":"Three APOA5 mutations [p.(Ser232_Leu235)del, p.Leu253Pro, p.Asp332ValfsX4] each impair a distinct combination of LPL activation, liposome binding, heparin binding, and LRP1/sortilin/SorLA receptor binding, as shown by structural modeling and in vitro functional assays; full-length apoA-V 3D model reveals that affected residues are critical structural determinants.","method":"Recombinant protein expression/purification, LPL activation assay, liposome-binding assays, heparin-binding assay, LRP1/sortilin/SorLA binding assays, 3D homology modeling","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with multiple mutants and multiple orthogonal functional assays plus structural modeling","pmids":["23307945"],"is_preprint":false},{"year":2014,"finding":"The hypertriglyceridemia-associated G185C (p.Gly185Cys, rs2075291) variant of apoA-V forms aberrant disulfide-linked heterodimers with plasma proteins including fibronectin and kininogen-1, sequestering >50% of G162C apoA-V in the lipoprotein-free fraction and impairing its lipoprotein-binding and TG-modulating functions.","method":"AAV2/8-mediated gene transfer in apoa5(-/-) mice, plasma fractionation, non-reducing SDS-PAGE immunoblot, immunoprecipitation followed by LC/MS-MS of human plasma from variant homozygotes","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo gene transfer, biochemical fractionation, and mass spectrometry in both mouse model and human plasma","pmids":["25127531"],"is_preprint":false},{"year":2014,"finding":"The APOA5 3' UTR variant c.*158C (rs2266788) creates a functional binding site for liver-expressed miR-485-5p, leading to post-transcriptional downregulation of APOA5 mRNA; this mechanism explains the hypertriglyceridemic effect of the APOA5*2 haplotype.","method":"Luciferase reporter assays in HEK293T and HuH-7 cells co-transfected with APOA5 3' UTR reporter and miR-485-5p precursor; miR-485-5p inhibitor rescue experiment; bioinformatic miRNA binding site prediction","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1-2 — functional reporter assay with allele-specific effect and inhibitor rescue, providing mechanistic explanation for variant-associated reduced APOA5 expression","pmids":["24387992"],"is_preprint":false},{"year":2014,"finding":"The APOA5 3' UTR variant rs2266788 C allele destroys a miR-3201 binding site, prolonging APOA5 mRNA half-life and increasing APOA5 expression levels, thereby elevating plasma triglycerides and contributing to coronary artery disease severity.","method":"Luciferase reporter assay with 3' UTR constructs, mRNA stability assay, genotyping in case-control cohort","journal":"Journal of the American College of Cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter and stability assay, single lab; opposite allele direction from miR-485-5p paper (rs2266788 C allele destroys miR-3201 site vs. creates miR-485-5p site), but mechanistic experiment was performed","pmids":["25034063"],"is_preprint":false},{"year":2005,"finding":"Thyroid hormone (T3) directly regulates APOA5 transcription through a functional DR4 thyroid hormone response element in the APOA5 promoter; USF1 and USF2 cooperate with TR at an adjacent E-box to synergistically activate APOA5 in a ligand-dependent manner, increasing apoAV levels and lowering triglycerides in rats.","method":"T3/TRβ ligand treatment of hepatocytes (mRNA and protein measurement), APOA5 promoter luciferase reporter assays, DR4 element identification, rat in vivo thyroid hormone depletion/repletion experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — promoter reporter assays with defined response element, in vivo rat model, multiple orthogonal approaches","pmids":["15941710"],"is_preprint":false},{"year":2018,"finding":"Protein restriction (PR) increases VLDL-bound APOA5 expression via the transcription factor CREBH, promoting VLDL-TG hydrolysis and clearance; constitutive mTORC1 activation blocks CREBH activation and blunts APOA5 induction, causing PR-resistant hypertriglyceridemia. PR also reduces VLDL-TG secretion independently of CREBH-APOA5.","method":"Mouse dietary protein restriction models, antisense oligonucleotide knockdown, Crebh KO mice, constitutive mTORC1 activation mice, VLDL turnover assays, human randomized controlled trial measuring VLDL APOA5","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1-2 — multiple genetic mouse models, mechanistic pathway epistasis, and human clinical validation","pmids":["30385734"],"is_preprint":false},{"year":2014,"finding":"ApoA5 knockdown in mice using antisense oligonucleotides increases plasma TG ~3-fold, decreases TG clearance, and reduces liver and skeletal muscle TG uptake; in high-fat-diet mice, ApoA5 ASO treatment protects against insulin resistance by decreasing diacylglycerol (DAG) content, reducing PKCε and PKCθ activation, and increasing insulin-stimulated AKT2 phosphorylation in liver and muscle.","method":"Antisense oligonucleotide knockdown of ApoA5 in mice, hyperinsulinemic-euglycemic clamps, tissue lipid fractionation (DAG/TG measurement), PKC activity assay, AKT2 phosphorylation by Western blot, plasma TG clearance","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — clean KO-equivalent ASO knockdown with defined metabolic phenotype and molecular pathway dissection","pmids":["25548259"],"is_preprint":false},{"year":2007,"finding":"Introduction of the APOA5*3-defining S19W allele into mice at a single chromosomal copy (via Hprt-targeted insertion) results in three-fold lower circulating human ApoAV plasma levels compared to the common APOA5*1 or APOA5*2 haplotypes, confirming that S19W is a functional variant that reduces protein secretion/plasma levels.","method":"Targeted single-copy haplotype insertion at Hprt locus in mice; plasma human ApoAV measurement by ELISA","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1-2 — precise in vivo knock-in model with quantitative protein measurement, single lab but rigorous allele-specific approach","pmids":["17936576"],"is_preprint":false},{"year":2020,"finding":"PC7 (PCSK7) binds to apoA-V and enhances its lysosomal degradation in a non-enzymatic fashion via an ER-lysosomal pathway; degradation is inhibited by bafilomycin A1, chloroquine, and NH4Cl. The natural PC7 R504H variant promotes Ser505 phosphorylation by Fam20C, and the phosphomimetic PC7-S505E degrades apoA-V less efficiently. In Pcsk7(-/-) mice on HFD, plasma apoA-V and adipocyte LPL activity are increased.","method":"Co-expression in HuH7 cells, co-immunoprecipitation, lysosomal inhibitor experiments, Fam20C phosphorylation assay, Pcsk7(-/-) mouse model with plasma apoA-V and LPL activity measurement","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro binding/degradation assays with mechanistic inhibitors, phosphorylation identification, and in vivo mouse model with consistent phenotype","pmids":["31945259"],"is_preprint":false},{"year":2006,"finding":"ApoAV interacts with apoC-III in a complex manner in hypertriglyceridemic patients; when controlling for apoC-III levels, the positive correlation between apoA-V and TG disappears, while apoC-III remains independently correlated with TG, suggesting apoC-III dominates over apoA-V in setting TG levels in severe HTG.","method":"Validated ELISA for plasma apoA-V measurement in HTG patients and controls; partial correlation analysis controlling for apoC-III","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 3 — human plasma measurement with statistical analysis; no direct molecular interaction experiment but defines functional epistasis between apoA-V and apoC-III","pmids":["16861622"],"is_preprint":false},{"year":2006,"finding":"Human patients homozygous for APOA5 truncation mutations (Q97X, Q148X, Q139X) have complete apoA-V deficiency in plasma, demonstrating that the C-terminal lipid-binding domain is required for stable circulating protein; these mutations result in severe type V hyperlipidemia with reduced postheparin LPL activity.","method":"APOA5 gene sequencing, plasma apoA-V measurement (ELISA/Western blot), postheparin LPL activity assay, apoB-100 kinetic studies, apoA-V lipoprotein association by Western blot","journal":"Current opinion in lipidology / Journal of internal medicine","confidence":"Medium","confidence_rationale":"Tier 2 — human loss-of-function genetics combined with direct protein measurement and functional LPL assay","pmids":["16531747","18324930"],"is_preprint":false},{"year":2024,"finding":"ApoA5 deficiency in hamsters (CRISPR/Cas9 knockout) causes hypertriglyceridemia and hepatic steatosis; mechanistically, loss of ApoA5 destabilizes NR1D1 mRNA in hepatocytes, reducing NR1D1 protein; AAV8-mediated hepatic NR1D1 overexpression ameliorates fatty liver without correcting plasma TG, identifying a novel ApoA5→NR1D1→NAFLD axis.","method":"CRISPR/Cas9 ApoA5 knockout hamster, AAV8 NR1D1 overexpression rescue, in vitro NR1D1 mRNA stability assay in HepG2 cells, plasma lipid and liver histology measurements","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1-2 — clean KO model with in vivo rescue and in vitro mechanistic follow-up, multiple orthogonal approaches","pmids":["38505614"],"is_preprint":false},{"year":2016,"finding":"DNA methylation at the CpG island in APOA5 exon 3 positively correlates with circulating TG levels and, in combination with APOA5 SNPs (-1131T>C, S19W, 724C>G), additively determines individual predisposition to hypertriglyceridemia, establishing epigenetic regulation of APOA5 as a mechanism modulating TG levels.","method":"Pyrosequencing of APOA5 promoter, exon 2, and exon 3 CpG island methylation in a recruit-by-genotype cohort; correlation analysis with plasma TG","journal":"Clinical science","confidence":"Low","confidence_rationale":"Tier 3 — association-level methylation measurement without functional validation of the causal epigenetic effect on gene expression","pmids":["27613158"],"is_preprint":false},{"year":2012,"finding":"Vitamin D-dependent APOA5 promoter polymorphism rs10750097 modulates APOA5 promoter activity in a 25-hydroxyvitamin D-dependent manner, as shown by allele-specific luciferase assays in HEP3B and HEK293 cells, affecting HDL-C levels.","method":"Luciferase reporter assays with allele-specific APOA5 promoter constructs in HEP3B and HEK293 cells treated with vitamin D; population genetic analysis","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 — functional promoter assay with allele-specific vitamin D response, single lab","pmids":["22425169"],"is_preprint":false}],"current_model":"ApoA5 is a liver-secreted apolipoprotein that lowers plasma triglycerides primarily by associating with the ANGPTL3/8 complex to relieve its inhibition of lipoprotein lipase (LPL), and secondarily by facilitating receptor-mediated uptake of TG-rich lipoproteins via LRP1, sortilin, and related receptors; its expression is transcriptionally upregulated by thyroid hormone (via a DR4 element in cooperation with USF1/USF2), by protein restriction (via CREBH/mTORC1), and by estrogen, while being post-transcriptionally downregulated by miR-485-5p binding to the APOA5*2 3' UTR variant and by PC7-mediated lysosomal degradation; loss-of-function mutations or the S19W signal-peptide variant reduce secretion and plasma levels, causing severe hypertriglyceridemia, while in the liver ApoA5 additionally stabilizes NR1D1 mRNA to protect against hepatic steatosis."},"narrative":{"teleology":[{"year":2005,"claim":"Establishing how the common S19W variant causes reduced ApoA5 function: the Trp-19 signal peptide impairs ER translocation, reducing secretion ~50%, providing the first molecular explanation for APOA5*3 haplotype-associated hypertriglyceridemia.","evidence":"Molecular modeling of signal peptide insertion angle plus secretion assays of SEAP fusion constructs in HepG2/Huh7 cells","pmids":["15941721"],"confidence":"High","gaps":["Whether S19W affects folding or stability beyond translocation was not tested","No in vivo secretion kinetics measured"]},{"year":2005,"claim":"Identifying a direct transcriptional mechanism: T3/TRβ activates APOA5 through a DR4 thyroid hormone response element, with USF1/USF2 synergistically co-activating at an adjacent E-box, linking thyroid status to TG metabolism.","evidence":"Promoter luciferase assays defining the DR4 element, hepatocyte T3 treatment, and rat thyroid hormone depletion/repletion in vivo","pmids":["15941710"],"confidence":"High","gaps":["Whether other nuclear receptors use the same DR4 element was not addressed","Contribution of USF1/2 cooperation in human liver not confirmed"]},{"year":2006,"claim":"Human loss-of-function genetics proved that APOA5 is required for normal TG metabolism: patients homozygous for truncation mutations (Q97X, Q139X, Q148X) have undetectable plasma ApoA5 and severe type V hyperlipidemia with reduced LPL activity.","evidence":"APOA5 sequencing, plasma ApoA5 ELISA, postheparin LPL activity in homozygous null patients","pmids":["16531747","18324930"],"confidence":"Medium","gaps":["Small number of patients limits genotype-phenotype range","Whether residual intracellular ApoA5 has hepatic functions was not examined"]},{"year":2007,"claim":"In vivo gain-of-function demonstrated that ApoA5 lowers TG by enhancing VLDL catabolism rather than reducing production, and additionally modulates HDL composition by increasing apoA-I/apoE content and LCAT activity.","evidence":"Adenoviral ApoA5 delivery in APOC3-transgenic mice with lipoprotein fractionation, LCAT activity, and cholesterol efflux assays","pmids":["17438339"],"confidence":"High","gaps":["Relative contribution of enhanced catabolism vs. receptor-mediated clearance not separated","HDL remodeling mechanism not molecularly defined"]},{"year":2007,"claim":"A precise knock-in model confirmed S19W as a causative functional variant in vivo: single-copy APOA5*3 mice had three-fold lower circulating ApoA5 than APOA5*1 mice, validating the secretion defect.","evidence":"Hprt-targeted single-copy haplotype insertion in mice with plasma ApoA5 ELISA","pmids":["17936576"],"confidence":"High","gaps":["TG phenotype in these mice not reported in this study","Human heterozygote secretion kinetics not measured"]},{"year":2008,"claim":"Structure-function mapping showed that rare APOA5 missense variants impair LPL activation and that C-terminal domains are essential for binding LDL-family receptors LRP1 and LR8, establishing ApoA5 as a dual-function molecule acting on both lipolysis and receptor-mediated uptake.","evidence":"In vitro LPL activity assays with VLDL substrate and receptor binding assays using recombinant mutant ApoA5 proteins","pmids":["18635818"],"confidence":"High","gaps":["Crystal structure of ApoA5-receptor complex not available","Whether LPL activation is direct or via ANGPTL modulation was unresolved at this time"]},{"year":2013,"claim":"Systematic dissection of three disease mutations revealed that individual residues distinctly contribute to liposome binding, heparin binding, LPL activation, and receptor interactions (LRP1, sortilin, SorLA), establishing that ApoA5's TG-lowering function is multivalent.","evidence":"Recombinant mutant proteins tested in LPL activation, liposome-binding, heparin-binding, and three receptor-binding assays; 3D homology model","pmids":["23307945"],"confidence":"High","gaps":["No high-resolution experimental structure","In vivo validation of individual mutant effects not performed"]},{"year":2014,"claim":"Post-transcriptional regulation of APOA5 was defined: the c.*158C variant (rs2266788) in the 3′ UTR creates a miR-485-5p binding site that downregulates APOA5 mRNA, providing a mechanistic basis for the APOA5*2 haplotype's association with hypertriglyceridemia.","evidence":"Allele-specific luciferase reporters in HEK293T and HuH-7 cells with miR-485-5p mimics and inhibitors","pmids":["24387992"],"confidence":"High","gaps":["Whether miR-485-5p levels vary physiologically to modulate ApoA5 is unknown","Conflicting report on same SNP and miR-3201 binding not reconciled"]},{"year":2014,"claim":"The G185C variant was shown to form aberrant disulfide-linked heterodimers with plasma proteins (fibronectin, kininogen-1), sequestering ApoA5 in the lipoprotein-free fraction and impairing its TG-lowering function—a gain-of-toxic-function mechanism distinct from simple loss of expression.","evidence":"AAV-mediated gene transfer in apoa5−/− mice, non-reducing SDS-PAGE, IP-LC/MS-MS of human homozygote plasma","pmids":["25127531"],"confidence":"High","gaps":["Whether other Cys-introducing variants show similar aberrant dimerization not tested","Structural basis of disulfide partner selection unknown"]},{"year":2014,"claim":"ApoA5 knockdown paradoxically protected against high-fat-diet insulin resistance by reducing tissue TG and DAG uptake, decreasing PKCε/PKCθ activation and enhancing AKT2 signaling, revealing that ApoA5-driven TRL clearance can promote lipotoxic insulin resistance in peripheral tissues.","evidence":"ASO knockdown in mice with hyperinsulinemic-euglycemic clamps, tissue DAG/TG fractionation, PKC translocation and AKT2 phosphorylation assays","pmids":["25548259"],"confidence":"High","gaps":["Whether this insulin-sensitizing effect of ApoA5 loss occurs in humans is unknown","Liver-specific vs. systemic effects not fully deconvoluted"]},{"year":2018,"claim":"A nutrient-sensing pathway was connected to APOA5: protein restriction induces APOA5 via CREBH, promoting VLDL-TG hydrolysis, while constitutive mTORC1 activation blocks CREBH and blunts this response, linking mTORC1-CREBH-APOA5 as a metabolic adaptation axis.","evidence":"Dietary protein restriction in wild-type, Crebh KO, and constitutively active mTORC1 mice; ASO knockdown; human randomized trial measuring VLDL-ApoA5","pmids":["30385734"],"confidence":"High","gaps":["Whether amino acid sensing or GCN2 pathway feeds into CREBH activation is not defined","Human trial was small and confirmatory"]},{"year":2020,"claim":"A new post-translational clearance mechanism was identified: PC7 (PCSK7) binds ApoA5 and routes it to lysosomal degradation non-enzymatically; the PC7-R504H variant's phosphorylation by Fam20C attenuates this degradation, and Pcsk7-knockout mice have elevated plasma ApoA5 and LPL activity.","evidence":"Co-IP in HuH7, lysosomal inhibitor rescue, Fam20C phosphorylation assay, Pcsk7−/− mouse on HFD","pmids":["31945259"],"confidence":"High","gaps":["Whether PC7-mediated degradation is regulated by metabolic signals is unknown","Stoichiometry and ER-to-lysosome trafficking route not fully mapped"]},{"year":2021,"claim":"The long-debated question of whether ApoA5 directly activates LPL was resolved: ApoA5 has no direct effect on LPL but instead lowers TG by physically associating with the ANGPTL3/8 complex and suppressing its LPL-inhibitory activity, with no effect on ANGPTL3, ANGPTL4, or ANGPTL4/8.","evidence":"IP-MS, biolayer interferometry, and functional LPL enzymatic assays with recombinant proteins","pmids":["33762177"],"confidence":"High","gaps":["Structural basis of the ApoA5–ANGPTL3/8 interaction not determined","Whether ApoA5 modulates ANGPTL3/8 secretion or only post-secretory activity is unclear"]},{"year":2024,"claim":"A liver-intrinsic role for ApoA5 beyond plasma TG control was established: ApoA5 deficiency destabilizes NR1D1 mRNA in hepatocytes, and NR1D1 overexpression rescues steatosis without correcting hypertriglyceridemia, revealing an ApoA5→NR1D1→NAFLD axis.","evidence":"CRISPR/Cas9 ApoA5 KO hamster, AAV8-NR1D1 rescue, NR1D1 mRNA stability assay in HepG2","pmids":["38505614"],"confidence":"High","gaps":["Mechanism by which ApoA5 stabilizes NR1D1 mRNA is unknown","Whether this axis operates in human NAFLD is untested","Whether ApoA5 affects other hepatic mRNAs not surveyed"]},{"year":null,"claim":"Key unresolved questions include the structural basis of ApoA5–ANGPTL3/8 interaction, how intracellular ApoA5 stabilizes NR1D1 mRNA, whether the insulin-sensitizing effect of ApoA5 loss translates to humans, and the physiological contexts in which PC7-mediated degradation is regulated.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of ApoA5 or its complexes","Mechanism of NR1D1 mRNA stabilization completely undefined","Human relevance of DAG/PKC-mediated insulin sensitization by ApoA5 loss not tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[4,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,3,4]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[3,4]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2,5,14]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,12]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,3,4,10]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[8,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,10]}],"complexes":["ANGPTL3/8-ApoA5 complex"],"partners":["ANGPTL3","ANGPTL8","LRP1","SORT1","SORL1","PCSK7","APOC3","USF1"],"other_free_text":[]},"mechanistic_narrative":"APOA5 encodes a liver-secreted apolipoprotein that is a central regulator of plasma triglyceride homeostasis, acting through multiple convergent mechanisms to promote triglyceride-rich lipoprotein (TRL) catabolism and clearance. ApoA5 lowers triglycerides primarily by binding and suppressing the ANGPTL3/8 complex, thereby relieving its inhibition of lipoprotein lipase (LPL), without directly activating LPL itself [PMID:33762177]; it also accelerates VLDL catabolism and facilitates receptor-mediated TRL uptake via LRP1, sortilin, and SorLA, functions that depend on C-terminal lipid-binding domains abolished by truncation or missense mutations [PMID:23307945, PMID:18635818]. Transcriptional regulation of APOA5 is mediated by thyroid hormone acting through a DR4 element with USF1/USF2 cooperation [PMID:15941710] and by CREBH under protein restriction conditions gated by mTORC1 [PMID:30385734], while post-transcriptionally the protein is downregulated by miR-485-5p targeting the APOA5*2 3′ UTR variant [PMID:24387992] and by PC7 (PCSK7)-mediated lysosomal degradation [PMID:31945259]. Loss-of-function mutations—including truncations (Q97X, Q139X, Q148X) and the signal-peptide variant S19W that halves secretion efficiency—cause severe hypertriglyceridemia (type V hyperlipidemia) [PMID:16531747, PMID:15941721], and ApoA5 deficiency additionally promotes hepatic steatosis through destabilization of NR1D1 mRNA independently of plasma TG effects [PMID:38505614]."},"prefetch_data":{"uniprot":{"accession":"Q6Q788","full_name":"Apolipoprotein A-V","aliases":["Apolipoprotein A5","Regeneration-associated protein 3"],"length_aa":366,"mass_kda":41.2,"function":"Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and an inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Binds heparin (PubMed:17326667)","subcellular_location":"Secreted; Early endosome; Late endosome; Golgi apparatus, trans-Golgi network","url":"https://www.uniprot.org/uniprotkb/Q6Q788/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOA5","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOA5","total_profiled":1310},"omim":[{"mim_id":"619324","title":"HYPERTRIGLYCERIDEMIA 2; HYTG2","url":"https://www.omim.org/entry/619324"},{"mim_id":"615947","title":"HYPERLIPOPROTEINEMIA, TYPE ID","url":"https://www.omim.org/entry/615947"},{"mim_id":"615385","title":"MICRO RNA 485; MIR485","url":"https://www.omim.org/entry/615385"},{"mim_id":"612757","title":"GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED HIGH DENSITY LIPOPROTEIN-BINDING PROTEIN 1; GPIHBP1","url":"https://www.omim.org/entry/612757"},{"mim_id":"606945","title":"LOW DENSITY LIPOPROTEIN RECEPTOR; LDLR","url":"https://www.omim.org/entry/606945"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":568.8}],"url":"https://www.proteinatlas.org/search/APOA5"},"hgnc":{"alias_symbol":["RAP3","APOA-V"],"prev_symbol":[]},"alphafold":{"accession":"Q6Q788","domains":[{"cath_id":"1.20.120.20","chopping":"109-265_272-316","consensus_level":"medium","plddt":85.621,"start":109,"end":316}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6Q788","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6Q788-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6Q788-F1-predicted_aligned_error_v6.png","plddt_mean":71.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOA5","jax_strain_url":"https://www.jax.org/strain/search?query=APOA5"},"sequence":{"accession":"Q6Q788","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6Q788.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6Q788/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6Q788"}},"corpus_meta":[{"pmid":"25487149","id":"PMC_25487149","title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25487149","citation_count":530,"is_preprint":false},{"pmid":"22239554","id":"PMC_22239554","title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.","date":"2012","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22239554","citation_count":201,"is_preprint":false},{"pmid":"15342688","id":"PMC_15342688","title":"Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15342688","citation_count":138,"is_preprint":false},{"pmid":"12697303","id":"PMC_12697303","title":"Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12697303","citation_count":105,"is_preprint":false},{"pmid":"12671030","id":"PMC_12671030","title":"Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12671030","citation_count":101,"is_preprint":false},{"pmid":"15941721","id":"PMC_15941721","title":"Determination of the functionality of common APOA5 polymorphisms.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15941721","citation_count":100,"is_preprint":false},{"pmid":"14729863","id":"PMC_14729863","title":"APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/14729863","citation_count":92,"is_preprint":false},{"pmid":"12937897","id":"PMC_12937897","title":"The single nucleotide polymorphism -1131T>C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia.","date":"2003","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/12937897","citation_count":78,"is_preprint":false},{"pmid":"16531747","id":"PMC_16531747","title":"APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency.","date":"2006","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/16531747","citation_count":76,"is_preprint":false},{"pmid":"17211608","id":"PMC_17211608","title":"APOA5 gene variation modulates the effects of dietary fat intake on body mass index and obesity risk in the Framingham Heart Study.","date":"2007","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17211608","citation_count":74,"is_preprint":false},{"pmid":"12752569","id":"PMC_12752569","title":"APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men.","date":"2003","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12752569","citation_count":73,"is_preprint":false},{"pmid":"33762177","id":"PMC_33762177","title":"ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition.","date":"2021","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/33762177","citation_count":70,"is_preprint":false},{"pmid":"15306190","id":"PMC_15306190","title":"APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease.","date":"2004","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/15306190","citation_count":66,"is_preprint":false},{"pmid":"16682041","id":"PMC_16682041","title":"The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study.","date":"2006","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16682041","citation_count":62,"is_preprint":false},{"pmid":"17768309","id":"PMC_17768309","title":"APOA5 variants and metabolic syndrome in Caucasians.","date":"2007","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/17768309","citation_count":60,"is_preprint":false},{"pmid":"25034063","id":"PMC_25034063","title":"A functional variant in APOA5/A4/C3/A1 gene cluster contributes to elevated triglycerides and severity of CAD by interfering with microRNA 3201 binding efficiency.","date":"2014","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25034063","citation_count":58,"is_preprint":false},{"pmid":"23000317","id":"PMC_23000317","title":"The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research.","date":"2012","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23000317","citation_count":57,"is_preprint":false},{"pmid":"21209257","id":"PMC_21209257","title":"APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population.","date":"2011","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/21209257","citation_count":56,"is_preprint":false},{"pmid":"28865324","id":"PMC_28865324","title":"The impact of APOA5, APOB, APOC3 and ABCA1 gene polymorphisms on ischemic stroke: Evidence from a meta-analysis.","date":"2017","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/28865324","citation_count":55,"is_preprint":false},{"pmid":"16474174","id":"PMC_16474174","title":"Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16474174","citation_count":55,"is_preprint":false},{"pmid":"16777114","id":"PMC_16777114","title":"Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism.","date":"2006","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16777114","citation_count":55,"is_preprint":false},{"pmid":"15941710","id":"PMC_15941710","title":"Thyroid hormone regulates the hypotriglyceridemic gene APOA5.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15941710","citation_count":54,"is_preprint":false},{"pmid":"26365669","id":"PMC_26365669","title":"Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects.","date":"2015","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26365669","citation_count":54,"is_preprint":false},{"pmid":"18635818","id":"PMC_18635818","title":"Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding.","date":"2008","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18635818","citation_count":52,"is_preprint":false},{"pmid":"24387992","id":"PMC_24387992","title":"An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site.","date":"2014","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24387992","citation_count":51,"is_preprint":false},{"pmid":"25548259","id":"PMC_25548259","title":"ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25548259","citation_count":51,"is_preprint":false},{"pmid":"27827461","id":"PMC_27827461","title":"Association and interaction of APOA5, BUD13, CETP, LIPA and health-related behavior with metabolic syndrome in a Taiwanese population.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27827461","citation_count":49,"is_preprint":false},{"pmid":"16861622","id":"PMC_16861622","title":"Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16861622","citation_count":48,"is_preprint":false},{"pmid":"18779834","id":"PMC_18779834","title":"APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia.","date":"2008","source":"Nature clinical practice. Cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18779834","citation_count":48,"is_preprint":false},{"pmid":"15604515","id":"PMC_15604515","title":"APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15604515","citation_count":48,"is_preprint":false},{"pmid":"28500476","id":"PMC_28500476","title":"Update on APOA5 Genetics: Toward a Better Understanding of Its Physiological Impact.","date":"2017","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/28500476","citation_count":47,"is_preprint":false},{"pmid":"17438339","id":"PMC_17438339","title":"Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice.","date":"2007","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/17438339","citation_count":47,"is_preprint":false},{"pmid":"19159622","id":"PMC_19159622","title":"The apolipoprotein A5 -1131T>C promoter polymorphism in Koreans: association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease.","date":"2008","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19159622","citation_count":47,"is_preprint":false},{"pmid":"22914552","id":"PMC_22914552","title":"APOA5 genotype modulates 2-y changes in lipid profile in response to weight-loss diet intervention: the Pounds Lost Trial.","date":"2012","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/22914552","citation_count":46,"is_preprint":false},{"pmid":"19056598","id":"PMC_19056598","title":"Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states.","date":"2008","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/19056598","citation_count":45,"is_preprint":false},{"pmid":"18324930","id":"PMC_18324930","title":"Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene.","date":"2008","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18324930","citation_count":45,"is_preprint":false},{"pmid":"21130994","id":"PMC_21130994","title":"Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21130994","citation_count":44,"is_preprint":false},{"pmid":"16321685","id":"PMC_16321685","title":"Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men.","date":"2006","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/16321685","citation_count":44,"is_preprint":false},{"pmid":"23468858","id":"PMC_23468858","title":"Effects of APOA5 -1131T>C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: evidence from a case-control study in China and a meta-analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23468858","citation_count":41,"is_preprint":false},{"pmid":"17032446","id":"PMC_17032446","title":"Triglyceride associated polymorphisms of the APOA5 gene have very different allele frequencies in Pune, India compared to Europeans.","date":"2006","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17032446","citation_count":41,"is_preprint":false},{"pmid":"16125709","id":"PMC_16125709","title":"SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population.","date":"2005","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16125709","citation_count":41,"is_preprint":false},{"pmid":"23307945","id":"PMC_23307945","title":"Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23307945","citation_count":40,"is_preprint":false},{"pmid":"30385734","id":"PMC_30385734","title":"Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30385734","citation_count":39,"is_preprint":false},{"pmid":"16887900","id":"PMC_16887900","title":"Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.","date":"2006","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16887900","citation_count":39,"is_preprint":false},{"pmid":"19910639","id":"PMC_19910639","title":"Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis.","date":"2009","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19910639","citation_count":39,"is_preprint":false},{"pmid":"21889769","id":"PMC_21889769","title":"Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.","date":"2011","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21889769","citation_count":38,"is_preprint":false},{"pmid":"26824674","id":"PMC_26824674","title":"Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26824674","citation_count":34,"is_preprint":false},{"pmid":"18601598","id":"PMC_18601598","title":"Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults.","date":"2008","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18601598","citation_count":34,"is_preprint":false},{"pmid":"17197160","id":"PMC_17197160","title":"The effect of APOA5 and APOC3 variants on lipid parameters in European Whites, Indian Asians and Afro-Caribbeans with type 2 diabetes.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17197160","citation_count":33,"is_preprint":false},{"pmid":"17142127","id":"PMC_17142127","title":"Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study.","date":"2006","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/17142127","citation_count":31,"is_preprint":false},{"pmid":"18263854","id":"PMC_18263854","title":"Influence of apoA-V gene variants on postprandial triglyceride metabolism: impact of gender.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18263854","citation_count":30,"is_preprint":false},{"pmid":"29263402","id":"PMC_29263402","title":"Genome-wide association study identifies a missense variant at APOA5 for coronary artery disease in Multi-Ethnic Cohorts from Southeast Asia.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29263402","citation_count":30,"is_preprint":false},{"pmid":"17222847","id":"PMC_17222847","title":"Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review.","date":"2007","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/17222847","citation_count":29,"is_preprint":false},{"pmid":"17726453","id":"PMC_17726453","title":"Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.","date":"2007","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/17726453","citation_count":29,"is_preprint":false},{"pmid":"24903888","id":"PMC_24903888","title":"Triglyceride-raising APOA5 genetic variants are associated with obesity and non-HDL-C in Chinese children and adolescents.","date":"2014","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/24903888","citation_count":28,"is_preprint":false},{"pmid":"16143024","id":"PMC_16143024","title":"Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.","date":"2005","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16143024","citation_count":28,"is_preprint":false},{"pmid":"25770687","id":"PMC_25770687","title":"APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25770687","citation_count":27,"is_preprint":false},{"pmid":"19018513","id":"PMC_19018513","title":"The association of common genetic variants in the APOA5, LPL and GCK genes with longitudinal changes in metabolic and cardiovascular traits.","date":"2008","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/19018513","citation_count":27,"is_preprint":false},{"pmid":"23656756","id":"PMC_23656756","title":"Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults.","date":"2013","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/23656756","citation_count":27,"is_preprint":false},{"pmid":"24690159","id":"PMC_24690159","title":"Consumption of whole grains and legumes modulates the genetic effect of the APOA5 -1131C variant on changes in triglyceride and apolipoprotein A-V concentrations in patients with impaired fasting glucose or newly diagnosed type 2 diabetes.","date":"2014","source":"Trials","url":"https://pubmed.ncbi.nlm.nih.gov/24690159","citation_count":27,"is_preprint":false},{"pmid":"16943456","id":"PMC_16943456","title":"Comparison of low-fat meal and high-fat meal on postprandial lipemic response in non-obese men according to the -1131T>C polymorphism of the apolipoprotein A5 (APOA5) gene (randomized cross-over design).","date":"2006","source":"Journal of the American College of Nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/16943456","citation_count":25,"is_preprint":false},{"pmid":"22517333","id":"PMC_22517333","title":"Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese - a cross-sectional data from the J-MICC Study.","date":"2012","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/22517333","citation_count":25,"is_preprint":false},{"pmid":"25308402","id":"PMC_25308402","title":"Association of USF1 and APOA5 polymorphisms with familial combined hyperlipidemia in an Italian population.","date":"2014","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/25308402","citation_count":24,"is_preprint":false},{"pmid":"29212154","id":"PMC_29212154","title":"Detection of susceptibility loci on APOA5 and COLEC12 associated with metabolic syndrome using a genome-wide association study in a Taiwanese population.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29212154","citation_count":24,"is_preprint":false},{"pmid":"21438666","id":"PMC_21438666","title":"Association of PON1 and APOA5 gene polymorphisms in a cohort of Indian patients having coronary artery disease with and without type 2 diabetes.","date":"2011","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/21438666","citation_count":24,"is_preprint":false},{"pmid":"24684850","id":"PMC_24684850","title":"Association of APOA5 rs662799 and rs3135506 polymorphisms with arterial hypertension in Moroccan patients.","date":"2014","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/24684850","citation_count":23,"is_preprint":false},{"pmid":"18468520","id":"PMC_18468520","title":"Association of APOA5 -1131T>C and S19W gene polymorphisms with both mild hypertriglyceridemia and hyperchylomicronemia in type 2 diabetic patients.","date":"2008","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18468520","citation_count":23,"is_preprint":false},{"pmid":"18537870","id":"PMC_18537870","title":"Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans.","date":"2008","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18537870","citation_count":22,"is_preprint":false},{"pmid":"17936576","id":"PMC_17936576","title":"In vivo characterization of human APOA5 haplotypes.","date":"2007","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17936576","citation_count":21,"is_preprint":false},{"pmid":"19344899","id":"PMC_19344899","title":"The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study.","date":"2009","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19344899","citation_count":21,"is_preprint":false},{"pmid":"20304614","id":"PMC_20304614","title":"The influence of the S19W SNP of the APOA5 gene on triglyceride levels in southern Brazil: interactions with the APOE gene, sex and menopause status.","date":"2010","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/20304614","citation_count":21,"is_preprint":false},{"pmid":"19447388","id":"PMC_19447388","title":"Modulation of phenotypic expression of APOA5 Q97X and L242P mutations.","date":"2009","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19447388","citation_count":20,"is_preprint":false},{"pmid":"20392444","id":"PMC_20392444","title":"APOA5-1131T>C genotype effects on apolipoprotein A5 and triglyceride levels in response to dietary intervention and regular exercise (DIRE) in hypertriglyceridemic subjects.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/20392444","citation_count":20,"is_preprint":false},{"pmid":"26397108","id":"PMC_26397108","title":"Effects of Polymorphisms in APOA4-APOA5-ZNF259-BUD13 Gene Cluster on Plasma Levels of Triglycerides and Risk of Coronary Heart Disease in a Chinese Han Population.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26397108","citation_count":20,"is_preprint":false},{"pmid":"20571505","id":"PMC_20571505","title":"A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/20571505","citation_count":20,"is_preprint":false},{"pmid":"29866721","id":"PMC_29866721","title":"Effects of polymorphisms in APOA5 on the plasma levels of triglycerides and risk of coronary heart disease in Jilin, northeast China: a case-control study.","date":"2018","source":"BMJ open","url":"https://pubmed.ncbi.nlm.nih.gov/29866721","citation_count":20,"is_preprint":false},{"pmid":"18549811","id":"PMC_18549811","title":"Interaction between APOA5 -1131T>C and APOE polymorphisms and their association with severe hypertriglyceridemia.","date":"2008","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18549811","citation_count":19,"is_preprint":false},{"pmid":"19932084","id":"PMC_19932084","title":"Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19932084","citation_count":19,"is_preprint":false},{"pmid":"25313938","id":"PMC_25313938","title":"Influences of APOA5 variants on plasma triglyceride levels in Uyghur population.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25313938","citation_count":19,"is_preprint":false},{"pmid":"25127531","id":"PMC_25127531","title":"Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291).","date":"2014","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25127531","citation_count":19,"is_preprint":false},{"pmid":"21993410","id":"PMC_21993410","title":"Resequencing the apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia.","date":"2011","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21993410","citation_count":19,"is_preprint":false},{"pmid":"20688329","id":"PMC_20688329","title":"The apolipoprotein A5 (APOA5) gene predisposes Caucasian children to elevated triglycerides and vitamin E (Four Provinces Study).","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/20688329","citation_count":19,"is_preprint":false},{"pmid":"22425169","id":"PMC_22425169","title":"Vitamin D dependent effects of APOA5 polymorphisms on HDL cholesterol.","date":"2012","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/22425169","citation_count":19,"is_preprint":false},{"pmid":"18946207","id":"PMC_18946207","title":"Changes of plasma lipids during weight reduction in females depends on APOA5 variants.","date":"2008","source":"Annals of nutrition & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18946207","citation_count":19,"is_preprint":false},{"pmid":"31945259","id":"PMC_31945259","title":"Proprotein convertase 7 (PCSK7) reduces apoA-V levels.","date":"2020","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/31945259","citation_count":18,"is_preprint":false},{"pmid":"32561169","id":"PMC_32561169","title":"Gene-environment interaction between APOA5 c.553G>T and pregnancy in hypertriglyceridemia-induced acute pancreatitis.","date":"2020","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/32561169","citation_count":18,"is_preprint":false},{"pmid":"28376804","id":"PMC_28376804","title":"Estrogen lowers triglyceride via regulating hepatic APOA5 expression.","date":"2017","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/28376804","citation_count":18,"is_preprint":false},{"pmid":"24694356","id":"PMC_24694356","title":"Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/24694356","citation_count":18,"is_preprint":false},{"pmid":"21846464","id":"PMC_21846464","title":"Two novel rare variants of APOA5 gene found in subjects with severe hypertriglyceridemia.","date":"2011","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21846464","citation_count":18,"is_preprint":false},{"pmid":"17157483","id":"PMC_17157483","title":"Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17157483","citation_count":18,"is_preprint":false},{"pmid":"27171122","id":"PMC_27171122","title":"APOA5 and APOA1 polymorphisms are associated with triglyceride levels in Mexican children.","date":"2016","source":"Pediatric obesity","url":"https://pubmed.ncbi.nlm.nih.gov/27171122","citation_count":18,"is_preprint":false},{"pmid":"28245265","id":"PMC_28245265","title":"Admixture mapping in two Mexican samples identifies significant associations of locus ancestry with triglyceride levels in the BUD13/ZNF259/APOA5 region and fine mapping points to rs964184 as the main driver of the association signal.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28245265","citation_count":17,"is_preprint":false},{"pmid":"26345861","id":"PMC_26345861","title":"Relationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26345861","citation_count":16,"is_preprint":false},{"pmid":"29211729","id":"PMC_29211729","title":"A promoter variant of the APOA5 gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29211729","citation_count":15,"is_preprint":false},{"pmid":"21548985","id":"PMC_21548985","title":"Relationship of APOA5, PPARγ and HL gene variants with serial changes in childhood body mass index and coronary artery disease risk factors in young adulthood.","date":"2011","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/21548985","citation_count":15,"is_preprint":false},{"pmid":"38505614","id":"PMC_38505614","title":"Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/38505614","citation_count":14,"is_preprint":false},{"pmid":"31165758","id":"PMC_31165758","title":"Association of BUD13-ZNF259-APOA5-APOA1-SIK3 cluster polymorphism in 11q23.3 and structure of APOA5 with increased plasma triglyceride levels in a Korean population.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31165758","citation_count":14,"is_preprint":false},{"pmid":"27613158","id":"PMC_27613158","title":"APOA5 genetic and epigenetic variability jointly regulate circulating triacylglycerol levels.","date":"2016","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/27613158","citation_count":14,"is_preprint":false},{"pmid":"20054229","id":"PMC_20054229","title":"Gene-gene interaction between APOA5 and USF1: two candidate genes for the metabolic syndrome.","date":"2009","source":"Obesity facts","url":"https://pubmed.ncbi.nlm.nih.gov/20054229","citation_count":14,"is_preprint":false},{"pmid":"28252576","id":"PMC_28252576","title":"APOA5 Gene Polymorphisms and Cardiovascular Diseases: Metaprediction in Global Populations.","date":"2017","source":"Nursing research","url":"https://pubmed.ncbi.nlm.nih.gov/28252576","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":59261,"output_tokens":4964,"usd":0.126121},"stage2":{"model":"claude-opus-4-6","input_tokens":8435,"output_tokens":3904,"usd":0.209663},"total_usd":0.335784,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2021,\n      \"finding\": \"ApoA5 lowers triglycerides by associating with and suppressing the ANGPTL3/8 complex, thereby relieving ANGPTL3/8-mediated LPL inhibition; ApoA5 has no direct effect on LPL itself, nor does it suppress LPL inhibition by ANGPTL3, ANGPTL4, or ANGPTL4/8 alone.\",\n      \"method\": \"Immunoprecipitation-MS, Western blotting, biolayer interferometry, functional LPL enzymatic assays, kinetic analyses of LPL activity\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical methods (IP-MS, biolayer interferometry, functional LPL assays) in a single rigorous study with clear mechanistic conclusion\",\n      \"pmids\": [\"33762177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The APOA5*3 haplotype-defining S19W (c.56C>G) variant reduces ApoAV secretion by ~50% from hepatic cells; molecular modeling shows Trp-19 increases the angle of insertion of the signal peptide at the lipid/water interface, predicting impaired translocation, confirmed by reduced secretion of a Trp-19-SEAP fusion protein vs. Ser-19-SEAP.\",\n      \"method\": \"Molecular modeling of signal peptide, in vitro secretion assay (HepG2 cells transfected with SEAP fusion constructs), in vitro transcription/translation assays, primer extension inhibition assays, luciferase reporter assays (Huh7 cells)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution/functional cell assay with mutagenesis, supported by molecular modeling and multiple orthogonal methods in a single study\",\n      \"pmids\": [\"15941721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ApoA5 delivered to livers of APOC3 transgenic mice reduces plasma TG via enhanced VLDL catabolism (not altered production), reduces apoC-III content in VLDL, and modulates HDL maturation by increasing apoA-I and apoE content and LCAT activity in HDL.\",\n      \"method\": \"Adenovirus-mediated hepatic gene transfer of apoA-V cDNA in APOC3 transgenic mice; plasma lipoprotein fractionation, LCAT activity assay, cholesterol efflux assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo gain-of-function with multiple biochemical readouts, mechanistic pathway placement\",\n      \"pmids\": [\"17438339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Several rare APOA5 missense variants (E255G, G271C, H321L, G185C) reduce in vitro LPL activation when using VLDL as substrate; truncation variants (Q139X, Q148X, G271C) abolish binding to LDL-family receptors LR8 and LRP1, indicating that C-terminal lipid-binding domains are required for receptor interaction.\",\n      \"method\": \"Sequencing of APOA5 in hypertriglyceridemic patients; in vitro LPL activity assay with VLDL substrate; receptor binding assays with LR8 and LRP1\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic and binding assays with multiple mutant constructs\",\n      \"pmids\": [\"18635818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Three APOA5 mutations [p.(Ser232_Leu235)del, p.Leu253Pro, p.Asp332ValfsX4] each impair a distinct combination of LPL activation, liposome binding, heparin binding, and LRP1/sortilin/SorLA receptor binding, as shown by structural modeling and in vitro functional assays; full-length apoA-V 3D model reveals that affected residues are critical structural determinants.\",\n      \"method\": \"Recombinant protein expression/purification, LPL activation assay, liposome-binding assays, heparin-binding assay, LRP1/sortilin/SorLA binding assays, 3D homology modeling\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with multiple mutants and multiple orthogonal functional assays plus structural modeling\",\n      \"pmids\": [\"23307945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The hypertriglyceridemia-associated G185C (p.Gly185Cys, rs2075291) variant of apoA-V forms aberrant disulfide-linked heterodimers with plasma proteins including fibronectin and kininogen-1, sequestering >50% of G162C apoA-V in the lipoprotein-free fraction and impairing its lipoprotein-binding and TG-modulating functions.\",\n      \"method\": \"AAV2/8-mediated gene transfer in apoa5(-/-) mice, plasma fractionation, non-reducing SDS-PAGE immunoblot, immunoprecipitation followed by LC/MS-MS of human plasma from variant homozygotes\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo gene transfer, biochemical fractionation, and mass spectrometry in both mouse model and human plasma\",\n      \"pmids\": [\"25127531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The APOA5 3' UTR variant c.*158C (rs2266788) creates a functional binding site for liver-expressed miR-485-5p, leading to post-transcriptional downregulation of APOA5 mRNA; this mechanism explains the hypertriglyceridemic effect of the APOA5*2 haplotype.\",\n      \"method\": \"Luciferase reporter assays in HEK293T and HuH-7 cells co-transfected with APOA5 3' UTR reporter and miR-485-5p precursor; miR-485-5p inhibitor rescue experiment; bioinformatic miRNA binding site prediction\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional reporter assay with allele-specific effect and inhibitor rescue, providing mechanistic explanation for variant-associated reduced APOA5 expression\",\n      \"pmids\": [\"24387992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The APOA5 3' UTR variant rs2266788 C allele destroys a miR-3201 binding site, prolonging APOA5 mRNA half-life and increasing APOA5 expression levels, thereby elevating plasma triglycerides and contributing to coronary artery disease severity.\",\n      \"method\": \"Luciferase reporter assay with 3' UTR constructs, mRNA stability assay, genotyping in case-control cohort\",\n      \"journal\": \"Journal of the American College of Cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter and stability assay, single lab; opposite allele direction from miR-485-5p paper (rs2266788 C allele destroys miR-3201 site vs. creates miR-485-5p site), but mechanistic experiment was performed\",\n      \"pmids\": [\"25034063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Thyroid hormone (T3) directly regulates APOA5 transcription through a functional DR4 thyroid hormone response element in the APOA5 promoter; USF1 and USF2 cooperate with TR at an adjacent E-box to synergistically activate APOA5 in a ligand-dependent manner, increasing apoAV levels and lowering triglycerides in rats.\",\n      \"method\": \"T3/TRβ ligand treatment of hepatocytes (mRNA and protein measurement), APOA5 promoter luciferase reporter assays, DR4 element identification, rat in vivo thyroid hormone depletion/repletion experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter reporter assays with defined response element, in vivo rat model, multiple orthogonal approaches\",\n      \"pmids\": [\"15941710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Protein restriction (PR) increases VLDL-bound APOA5 expression via the transcription factor CREBH, promoting VLDL-TG hydrolysis and clearance; constitutive mTORC1 activation blocks CREBH activation and blunts APOA5 induction, causing PR-resistant hypertriglyceridemia. PR also reduces VLDL-TG secretion independently of CREBH-APOA5.\",\n      \"method\": \"Mouse dietary protein restriction models, antisense oligonucleotide knockdown, Crebh KO mice, constitutive mTORC1 activation mice, VLDL turnover assays, human randomized controlled trial measuring VLDL APOA5\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple genetic mouse models, mechanistic pathway epistasis, and human clinical validation\",\n      \"pmids\": [\"30385734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ApoA5 knockdown in mice using antisense oligonucleotides increases plasma TG ~3-fold, decreases TG clearance, and reduces liver and skeletal muscle TG uptake; in high-fat-diet mice, ApoA5 ASO treatment protects against insulin resistance by decreasing diacylglycerol (DAG) content, reducing PKCε and PKCθ activation, and increasing insulin-stimulated AKT2 phosphorylation in liver and muscle.\",\n      \"method\": \"Antisense oligonucleotide knockdown of ApoA5 in mice, hyperinsulinemic-euglycemic clamps, tissue lipid fractionation (DAG/TG measurement), PKC activity assay, AKT2 phosphorylation by Western blot, plasma TG clearance\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO-equivalent ASO knockdown with defined metabolic phenotype and molecular pathway dissection\",\n      \"pmids\": [\"25548259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Introduction of the APOA5*3-defining S19W allele into mice at a single chromosomal copy (via Hprt-targeted insertion) results in three-fold lower circulating human ApoAV plasma levels compared to the common APOA5*1 or APOA5*2 haplotypes, confirming that S19W is a functional variant that reduces protein secretion/plasma levels.\",\n      \"method\": \"Targeted single-copy haplotype insertion at Hprt locus in mice; plasma human ApoAV measurement by ELISA\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — precise in vivo knock-in model with quantitative protein measurement, single lab but rigorous allele-specific approach\",\n      \"pmids\": [\"17936576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PC7 (PCSK7) binds to apoA-V and enhances its lysosomal degradation in a non-enzymatic fashion via an ER-lysosomal pathway; degradation is inhibited by bafilomycin A1, chloroquine, and NH4Cl. The natural PC7 R504H variant promotes Ser505 phosphorylation by Fam20C, and the phosphomimetic PC7-S505E degrades apoA-V less efficiently. In Pcsk7(-/-) mice on HFD, plasma apoA-V and adipocyte LPL activity are increased.\",\n      \"method\": \"Co-expression in HuH7 cells, co-immunoprecipitation, lysosomal inhibitor experiments, Fam20C phosphorylation assay, Pcsk7(-/-) mouse model with plasma apoA-V and LPL activity measurement\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro binding/degradation assays with mechanistic inhibitors, phosphorylation identification, and in vivo mouse model with consistent phenotype\",\n      \"pmids\": [\"31945259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ApoAV interacts with apoC-III in a complex manner in hypertriglyceridemic patients; when controlling for apoC-III levels, the positive correlation between apoA-V and TG disappears, while apoC-III remains independently correlated with TG, suggesting apoC-III dominates over apoA-V in setting TG levels in severe HTG.\",\n      \"method\": \"Validated ELISA for plasma apoA-V measurement in HTG patients and controls; partial correlation analysis controlling for apoC-III\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — human plasma measurement with statistical analysis; no direct molecular interaction experiment but defines functional epistasis between apoA-V and apoC-III\",\n      \"pmids\": [\"16861622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Human patients homozygous for APOA5 truncation mutations (Q97X, Q148X, Q139X) have complete apoA-V deficiency in plasma, demonstrating that the C-terminal lipid-binding domain is required for stable circulating protein; these mutations result in severe type V hyperlipidemia with reduced postheparin LPL activity.\",\n      \"method\": \"APOA5 gene sequencing, plasma apoA-V measurement (ELISA/Western blot), postheparin LPL activity assay, apoB-100 kinetic studies, apoA-V lipoprotein association by Western blot\",\n      \"journal\": \"Current opinion in lipidology / Journal of internal medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — human loss-of-function genetics combined with direct protein measurement and functional LPL assay\",\n      \"pmids\": [\"16531747\", \"18324930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ApoA5 deficiency in hamsters (CRISPR/Cas9 knockout) causes hypertriglyceridemia and hepatic steatosis; mechanistically, loss of ApoA5 destabilizes NR1D1 mRNA in hepatocytes, reducing NR1D1 protein; AAV8-mediated hepatic NR1D1 overexpression ameliorates fatty liver without correcting plasma TG, identifying a novel ApoA5→NR1D1→NAFLD axis.\",\n      \"method\": \"CRISPR/Cas9 ApoA5 knockout hamster, AAV8 NR1D1 overexpression rescue, in vitro NR1D1 mRNA stability assay in HepG2 cells, plasma lipid and liver histology measurements\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — clean KO model with in vivo rescue and in vitro mechanistic follow-up, multiple orthogonal approaches\",\n      \"pmids\": [\"38505614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DNA methylation at the CpG island in APOA5 exon 3 positively correlates with circulating TG levels and, in combination with APOA5 SNPs (-1131T>C, S19W, 724C>G), additively determines individual predisposition to hypertriglyceridemia, establishing epigenetic regulation of APOA5 as a mechanism modulating TG levels.\",\n      \"method\": \"Pyrosequencing of APOA5 promoter, exon 2, and exon 3 CpG island methylation in a recruit-by-genotype cohort; correlation analysis with plasma TG\",\n      \"journal\": \"Clinical science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — association-level methylation measurement without functional validation of the causal epigenetic effect on gene expression\",\n      \"pmids\": [\"27613158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Vitamin D-dependent APOA5 promoter polymorphism rs10750097 modulates APOA5 promoter activity in a 25-hydroxyvitamin D-dependent manner, as shown by allele-specific luciferase assays in HEP3B and HEK293 cells, affecting HDL-C levels.\",\n      \"method\": \"Luciferase reporter assays with allele-specific APOA5 promoter constructs in HEP3B and HEK293 cells treated with vitamin D; population genetic analysis\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter assay with allele-specific vitamin D response, single lab\",\n      \"pmids\": [\"22425169\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ApoA5 is a liver-secreted apolipoprotein that lowers plasma triglycerides primarily by associating with the ANGPTL3/8 complex to relieve its inhibition of lipoprotein lipase (LPL), and secondarily by facilitating receptor-mediated uptake of TG-rich lipoproteins via LRP1, sortilin, and related receptors; its expression is transcriptionally upregulated by thyroid hormone (via a DR4 element in cooperation with USF1/USF2), by protein restriction (via CREBH/mTORC1), and by estrogen, while being post-transcriptionally downregulated by miR-485-5p binding to the APOA5*2 3' UTR variant and by PC7-mediated lysosomal degradation; loss-of-function mutations or the S19W signal-peptide variant reduce secretion and plasma levels, causing severe hypertriglyceridemia, while in the liver ApoA5 additionally stabilizes NR1D1 mRNA to protect against hepatic steatosis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"APOA5 encodes a liver-secreted apolipoprotein that is a central regulator of plasma triglyceride homeostasis, acting through multiple convergent mechanisms to promote triglyceride-rich lipoprotein (TRL) catabolism and clearance. ApoA5 lowers triglycerides primarily by binding and suppressing the ANGPTL3/8 complex, thereby relieving its inhibition of lipoprotein lipase (LPL), without directly activating LPL itself [PMID:33762177]; it also accelerates VLDL catabolism and facilitates receptor-mediated TRL uptake via LRP1, sortilin, and SorLA, functions that depend on C-terminal lipid-binding domains abolished by truncation or missense mutations [PMID:23307945, PMID:18635818]. Transcriptional regulation of APOA5 is mediated by thyroid hormone acting through a DR4 element with USF1/USF2 cooperation [PMID:15941710] and by CREBH under protein restriction conditions gated by mTORC1 [PMID:30385734], while post-transcriptionally the protein is downregulated by miR-485-5p targeting the APOA5*2 3′ UTR variant [PMID:24387992] and by PC7 (PCSK7)-mediated lysosomal degradation [PMID:31945259]. Loss-of-function mutations—including truncations (Q97X, Q139X, Q148X) and the signal-peptide variant S19W that halves secretion efficiency—cause severe hypertriglyceridemia (type V hyperlipidemia) [PMID:16531747, PMID:15941721], and ApoA5 deficiency additionally promotes hepatic steatosis through destabilization of NR1D1 mRNA independently of plasma TG effects [PMID:38505614].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing how the common S19W variant causes reduced ApoA5 function: the Trp-19 signal peptide impairs ER translocation, reducing secretion ~50%, providing the first molecular explanation for APOA5*3 haplotype-associated hypertriglyceridemia.\",\n      \"evidence\": \"Molecular modeling of signal peptide insertion angle plus secretion assays of SEAP fusion constructs in HepG2/Huh7 cells\",\n      \"pmids\": [\"15941721\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S19W affects folding or stability beyond translocation was not tested\", \"No in vivo secretion kinetics measured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying a direct transcriptional mechanism: T3/TRβ activates APOA5 through a DR4 thyroid hormone response element, with USF1/USF2 synergistically co-activating at an adjacent E-box, linking thyroid status to TG metabolism.\",\n      \"evidence\": \"Promoter luciferase assays defining the DR4 element, hepatocyte T3 treatment, and rat thyroid hormone depletion/repletion in vivo\",\n      \"pmids\": [\"15941710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other nuclear receptors use the same DR4 element was not addressed\", \"Contribution of USF1/2 cooperation in human liver not confirmed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Human loss-of-function genetics proved that APOA5 is required for normal TG metabolism: patients homozygous for truncation mutations (Q97X, Q139X, Q148X) have undetectable plasma ApoA5 and severe type V hyperlipidemia with reduced LPL activity.\",\n      \"evidence\": \"APOA5 sequencing, plasma ApoA5 ELISA, postheparin LPL activity in homozygous null patients\",\n      \"pmids\": [\"16531747\", \"18324930\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small number of patients limits genotype-phenotype range\", \"Whether residual intracellular ApoA5 has hepatic functions was not examined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"In vivo gain-of-function demonstrated that ApoA5 lowers TG by enhancing VLDL catabolism rather than reducing production, and additionally modulates HDL composition by increasing apoA-I/apoE content and LCAT activity.\",\n      \"evidence\": \"Adenoviral ApoA5 delivery in APOC3-transgenic mice with lipoprotein fractionation, LCAT activity, and cholesterol efflux assays\",\n      \"pmids\": [\"17438339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of enhanced catabolism vs. receptor-mediated clearance not separated\", \"HDL remodeling mechanism not molecularly defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"A precise knock-in model confirmed S19W as a causative functional variant in vivo: single-copy APOA5*3 mice had three-fold lower circulating ApoA5 than APOA5*1 mice, validating the secretion defect.\",\n      \"evidence\": \"Hprt-targeted single-copy haplotype insertion in mice with plasma ApoA5 ELISA\",\n      \"pmids\": [\"17936576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TG phenotype in these mice not reported in this study\", \"Human heterozygote secretion kinetics not measured\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Structure-function mapping showed that rare APOA5 missense variants impair LPL activation and that C-terminal domains are essential for binding LDL-family receptors LRP1 and LR8, establishing ApoA5 as a dual-function molecule acting on both lipolysis and receptor-mediated uptake.\",\n      \"evidence\": \"In vitro LPL activity assays with VLDL substrate and receptor binding assays using recombinant mutant ApoA5 proteins\",\n      \"pmids\": [\"18635818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of ApoA5-receptor complex not available\", \"Whether LPL activation is direct or via ANGPTL modulation was unresolved at this time\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Systematic dissection of three disease mutations revealed that individual residues distinctly contribute to liposome binding, heparin binding, LPL activation, and receptor interactions (LRP1, sortilin, SorLA), establishing that ApoA5's TG-lowering function is multivalent.\",\n      \"evidence\": \"Recombinant mutant proteins tested in LPL activation, liposome-binding, heparin-binding, and three receptor-binding assays; 3D homology model\",\n      \"pmids\": [\"23307945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution experimental structure\", \"In vivo validation of individual mutant effects not performed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Post-transcriptional regulation of APOA5 was defined: the c.*158C variant (rs2266788) in the 3′ UTR creates a miR-485-5p binding site that downregulates APOA5 mRNA, providing a mechanistic basis for the APOA5*2 haplotype's association with hypertriglyceridemia.\",\n      \"evidence\": \"Allele-specific luciferase reporters in HEK293T and HuH-7 cells with miR-485-5p mimics and inhibitors\",\n      \"pmids\": [\"24387992\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether miR-485-5p levels vary physiologically to modulate ApoA5 is unknown\", \"Conflicting report on same SNP and miR-3201 binding not reconciled\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The G185C variant was shown to form aberrant disulfide-linked heterodimers with plasma proteins (fibronectin, kininogen-1), sequestering ApoA5 in the lipoprotein-free fraction and impairing its TG-lowering function—a gain-of-toxic-function mechanism distinct from simple loss of expression.\",\n      \"evidence\": \"AAV-mediated gene transfer in apoa5−/− mice, non-reducing SDS-PAGE, IP-LC/MS-MS of human homozygote plasma\",\n      \"pmids\": [\"25127531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other Cys-introducing variants show similar aberrant dimerization not tested\", \"Structural basis of disulfide partner selection unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"ApoA5 knockdown paradoxically protected against high-fat-diet insulin resistance by reducing tissue TG and DAG uptake, decreasing PKCε/PKCθ activation and enhancing AKT2 signaling, revealing that ApoA5-driven TRL clearance can promote lipotoxic insulin resistance in peripheral tissues.\",\n      \"evidence\": \"ASO knockdown in mice with hyperinsulinemic-euglycemic clamps, tissue DAG/TG fractionation, PKC translocation and AKT2 phosphorylation assays\",\n      \"pmids\": [\"25548259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this insulin-sensitizing effect of ApoA5 loss occurs in humans is unknown\", \"Liver-specific vs. systemic effects not fully deconvoluted\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A nutrient-sensing pathway was connected to APOA5: protein restriction induces APOA5 via CREBH, promoting VLDL-TG hydrolysis, while constitutive mTORC1 activation blocks CREBH and blunts this response, linking mTORC1-CREBH-APOA5 as a metabolic adaptation axis.\",\n      \"evidence\": \"Dietary protein restriction in wild-type, Crebh KO, and constitutively active mTORC1 mice; ASO knockdown; human randomized trial measuring VLDL-ApoA5\",\n      \"pmids\": [\"30385734\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether amino acid sensing or GCN2 pathway feeds into CREBH activation is not defined\", \"Human trial was small and confirmatory\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A new post-translational clearance mechanism was identified: PC7 (PCSK7) binds ApoA5 and routes it to lysosomal degradation non-enzymatically; the PC7-R504H variant's phosphorylation by Fam20C attenuates this degradation, and Pcsk7-knockout mice have elevated plasma ApoA5 and LPL activity.\",\n      \"evidence\": \"Co-IP in HuH7, lysosomal inhibitor rescue, Fam20C phosphorylation assay, Pcsk7−/− mouse on HFD\",\n      \"pmids\": [\"31945259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PC7-mediated degradation is regulated by metabolic signals is unknown\", \"Stoichiometry and ER-to-lysosome trafficking route not fully mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The long-debated question of whether ApoA5 directly activates LPL was resolved: ApoA5 has no direct effect on LPL but instead lowers TG by physically associating with the ANGPTL3/8 complex and suppressing its LPL-inhibitory activity, with no effect on ANGPTL3, ANGPTL4, or ANGPTL4/8.\",\n      \"evidence\": \"IP-MS, biolayer interferometry, and functional LPL enzymatic assays with recombinant proteins\",\n      \"pmids\": [\"33762177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the ApoA5–ANGPTL3/8 interaction not determined\", \"Whether ApoA5 modulates ANGPTL3/8 secretion or only post-secretory activity is unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A liver-intrinsic role for ApoA5 beyond plasma TG control was established: ApoA5 deficiency destabilizes NR1D1 mRNA in hepatocytes, and NR1D1 overexpression rescues steatosis without correcting hypertriglyceridemia, revealing an ApoA5→NR1D1→NAFLD axis.\",\n      \"evidence\": \"CRISPR/Cas9 ApoA5 KO hamster, AAV8-NR1D1 rescue, NR1D1 mRNA stability assay in HepG2\",\n      \"pmids\": [\"38505614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which ApoA5 stabilizes NR1D1 mRNA is unknown\", \"Whether this axis operates in human NAFLD is untested\", \"Whether ApoA5 affects other hepatic mRNAs not surveyed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of ApoA5–ANGPTL3/8 interaction, how intracellular ApoA5 stabilizes NR1D1 mRNA, whether the insulin-sensitizing effect of ApoA5 loss translates to humans, and the physiological contexts in which PC7-mediated degradation is regulated.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of ApoA5 or its complexes\", \"Mechanism of NR1D1 mRNA stabilization completely undefined\", \"Human relevance of DAG/PKC-mediated insulin sensitization by ApoA5 loss not tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 4]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 5, 14]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 3, 4, 10]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 10]}\n    ],\n    \"complexes\": [\n      \"ANGPTL3/8-ApoA5 complex\"\n    ],\n    \"partners\": [\n      \"ANGPTL3\",\n      \"ANGPTL8\",\n      \"LRP1\",\n      \"SORT1\",\n      \"SORL1\",\n      \"PCSK7\",\n      \"APOC3\",\n      \"USF1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}